Biotech Values

[iandy]

I am wondering what was the EMA rationale for restricting Iclusig use to second generation TKI failures. I thought all the data indicates that making Gleevec failures try another drug first would not be in the best interests of the patients.
The company seems to be oblivious to the label restrictions. I think if would be better if they addressed the issue.